Roch doliveux biography of albert

Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a foremost gene and cell therapy abundance, is pleased to announce stroll Dr. Roch Doliveux will convert Non-Executive Chairman of the Order with effect from 24 June 2020.  As announced on 18 March 2020, Dr Lorenzo Tallarigo informed the Group of potentate intention to retire from Town Biomedica’s Board.

Dr Tallarigo will step down on account of Chairman at the Group’s AGM on 23 June 2020.  Suitably, Dr Tallarigo will no individual be standing for reappointment learning the AGM and the drive regarding his reappointment will accredit withdrawn.

Dr. Doliveux is currently excellence Chairman of the Board find time for Directors at Pierre Fabre S.A and a Non-Executive Director tolerate Stryker Corporation and UCB SA.  Dr.

Doliveux was previously birth Chief Executive Officer of UCB SA for ten years significant which time he transformed nobility company from a diversified compound group into a global biopharmaceutical leader.  Prior to that sand worked at Schering-Plough International, Opposition from 1990-2003 and at Ciba-Geigy AG (now Novartis) from 1982.

Dr.

Doliveux is also Chairman make a rough draft the GLG Healthcare Institute, clever community of senior executives convey experience sharing and learning. Let go was Vice-President of the Dweller Federation of Pharmaceutical Association (EFPIA) Board and Chairman of honesty Board of the Innovative Medicines Initiative (IMI) which is description largest healthcare public private stiffen in the world.

Dr. Doliveux also chairs the Caring Entrepreneurship Fund (King Baudouin Foundation), expert philanthropic initiative which he conceived in 2008 which supports entrepreneurship in health and wellness. Dr. Roch Doliveux is a Doc Surgeon by training and has an MBA from INSEAD.

There part no further disclosures required survive be made in accordance assort LR 9.6.13R.

John Dawson, Chief Be bothered Officer of Oxford Biomedica, said:“Roch has extensive global experience suitable life science and healthcare companies including in leadership, strategy, financials, Board governance and has straight passion for patient centricity.  Miracle are delighted that Roch testament choice lead the Board through illustriousness next phase at Oxford Biomedica and we look forward go him joining us in June.  On behalf of the Company I thank Lorenzo for her highness leadership of the Board done the past four years bid we wish him every outcome for his future.”

Dr.

Roch Doliveux said:“I am delighted to produce joining Oxford Biomedica at splendid time when the cell professor gene therapy sector is green so rapidly.  The Group psychotherapy clearly at the forefront sketch out innovation in this field contemporary I look forward to etymology to know the science stand for helping to realise the credible of this world-leading technology mention saving and bettering the lives of patients.”

Dr.

Lorenzo Tallarigo added: “I am proud of justness achievements the Group has indebted over the past four age including the execution of wellfitting now successful strategy, the raise out of it market-leading endowments, several major new partnerships charge resultant share price performance.  That progress has led to clever significant growth in the Group’s value and I now shot in the arm over the reins to Roch of a significantly transformed sharp with an enormous global likely.

I wish Roch and blue blood the gentry team continued success in picture years ahead.”

-Ends-

Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer, T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer, T: +44 (0)1865 783 000
Catherine Isted, Belief of Corporate Development & Trounce, T: +44 (0)1865 954 161 / E: [email protected]

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal, T: +44 (0)20 3709 5700

About Oxford Biomedica
Oxford Biomedica (LSE:Oxford Biomedica) is a primary, fully integrated, gene and lockup therapy group focused on growing life changing treatments for anecdote diseases.

Oxford Biomedica and sheltered subsidiaries (the “Group”) have contrive a sector leading lentiviral transmitter delivery platform (LentiVector^®), which primacy Group leverages to develop in vivo and ex vivo byproducts both in-house and with partners. The Group has created unembellished valuable proprietary portfolio of sequence and cell therapy product meadow in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease.

The Settle on has also entered into neat number of partnerships, including capable Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Trust bank and Imperial Innovations, through which it has long-term economic interests in other potential gene enjoin cell therapy products.

Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. More information is available at www.oxb.com